Celltrion
068270KOSPI🇰🇷Healthcare · Biotechnology
Last updated: 12h ago
52-Week Range
Company Overview
Celltrion, Inc., a biopharmaceutical company, engages in the development, production, and sale of various therapeutic proteins for the treatment of oncology diseases. It operates through Biopharmaceutical Medicines, Chemical Medicines, and Others segments. The company offers biosimilars, including R
🤖 AI Stock Analysis
📊 Valuation: PER of 64.87 and Forward PER of 34.0 suggest a premium valuation based on current earnings, but the valuation burden may ease reflecting future growth potential. PBR of 2.69 indicates a premium relative to asset value.
💰 Profitability: ROE of 4.36% is somewhat low, but net profit margin of 18.94% and operating profit margin of 29.29% demonstrate high profitability.
📈 Growth: With a revenue growth rate of 16.7%, the profit growth rate of 296.8% indicates very strong and rapid growth is expected.
💵 Dividend: The dividend yield is low at 0.37%, and a payout ratio of 19.78% suggests a relatively low proportion of earnings are distributed as dividends.
💬 Summary: Future growth potential is anticipated based on high profit growth, but current valuation concerns should be considered. Profitability is generally sound.
AI-generated reference material. Not investment advice.